HomeGreater Than Icon
Gland Pharma LtdGreater Than Icon
Gland Pharma Ltd Financials
Company Logo

Gland Pharma Ltd Financial Statement

Gland Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue1120.79
Operating Expense699.19
Net Profit281.71
Net Profit Margin25.13
Earning Per Share17.10
EBIDTA419.83
Effective Tax Rate22.85

Gland Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual4,167.43
Operating Expenses Annual2,758.65
Operating Profit Annual1,575.45
Interest Annual7.84
Depreciation157.99
Net Profit Annual1,043.33
Tax Annual362.17

Gland Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning1,905.22
Cash Flow from Operations1,135.97
Cash Flow from Investing-2,917.58
Cash Flow from Financing-7.40
Cash Flow at the End116.21

Gland Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)37.80
PBIT Margin (%)33.91
PBT Margin (%)29.58
Net PROFIT Margin (%)25.04
Return On Networth / Equity (%)12.31
Return On Networth /Employed (%)16.65
Return On Assets (%)12.27
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)0.49

Gland Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual1,693.73
Total Current Assets Annual4,571.33
Non Current Assets Annual4,969.76
Total Shareholders Funds Annual8,995.29
Total Assets Annual9,541.09

Gland Pharma Ltd Earning Calls

EPS (INR)

Expected

9.92

Reported

9.93

Surprise

0.10%

Jun 2024

EPS beaten by 0.10%

Mar 2024

EPS beaten by 0.11%

Dec 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 5, 2024, Gland Pharma Ltd has a market capitalization of 30,338.03 Cr. Value Research classifies it as a Large-Cap company.
Yes, Gland Pharma Ltd is debt-free with a debt-to-equity ratio of 0.00.
In FY 2023 , Gland Pharma Ltd recorded a total revenue of approximately 4,167.43 Cr marking a significant milestone in the company's financial performance.
Gland Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.3% and -0.0% annually, respectively..
Gland Pharma Ltd's current PE ratio is 29.08.
Gland Pharma Ltd's ROCE averaged 17.2% from the FY ending March 2022 to 2024, with a median of 15.7%. It peaked at 22.7% in March 2022, reflecting strong capital efficiency over the period..
Gland Pharma Ltd's latest EBIT is Rs. 1,413.34 Cr, surpassing the average EBIT of Rs. 1,364.48 Cr over the 5 years..